TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18826157

Group type: EXPERIMENTAL
Intervention: Shen Shuai Fang + western medicine
Number of subjects: 125

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 125
Study: 16874591

Group type: EXPERIMENTAL
Intervention: Barefoot training
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ski boot training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (ankle brace)
Number of subjects: 63
Study: 15213369

Group type: EXPERIMENTAL
Intervention: i.v. netilmicin every 24 h (initially), then every 48 h for safety in premature group
Number of subjects: 80
Study: 10868311

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) interferon alfa‐n3 (10 million units)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) interferon alfa‐n3 (10 million units)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SQ) interferon alfa‐n3 (10 million units)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All routes (i.v., i.m., SQ)
Number of subjects: 6
Study: 9116382

Group type: EXPERIMENTAL
Intervention: Talking periods (stress and relaxation)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Initial 11-minute silent period
Number of subjects: 42

Group type: COMPARATOR
Intervention: Silent period
Number of subjects: 42
Study: 1417314

Group type: EXPERIMENTAL
Intervention: Endolymphatic administration of kanamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular administration of kanamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lymphotropic administration of kanamycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endolymphatic therapy during postoperative period
Number of subjects: 0
Study: 6519841

Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg, four times a day for 3 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg, four times a day for 3 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30383495

Group type: EXPERIMENTAL
Intervention: IDegLira (insulin degludec/liraglutide)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Basal insulin
Number of subjects: 344

Group type: COMPARATOR
Intervention: Unchanged GLP-1RA
Number of subjects: 344
Study: 29791247

Group type: EXPERIMENTAL
Intervention: Family-support intervention delivered by the interprofessional ICU team
Number of subjects: 1420
Study: 26093599

Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (DHEA) 100 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 23589465

Group type: EXPERIMENTAL
Intervention: (129) Xe MRI
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (3) He MRI
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (129) Xe MRI COV
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (3) He MRI COV
Number of subjects: 7
Study: 21339413

Group type: EXPERIMENTAL
Intervention: Early appendectomy (within 24 hours of admission)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Interval appendectomy (6-8 weeks after diagnosis)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Early appendectomy
Number of subjects: 131

Group type: COMPARATOR
Intervention: Interval appendectomy
Number of subjects: 131
Study: 19118791

Group type: EXPERIMENTAL
Intervention: Low back pain (LBP) group
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (without LBP)
Number of subjects: 13
Study: 18039102

Group type: EXPERIMENTAL
Intervention: Cell-based cardiac repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cell-based strategies
Number of subjects: 0
Study: 15054445

Group type: EXPERIMENTAL
Intervention: Haematopoietic growth factors (HGF) plus chemotherapy
Number of subjects: 779

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 779
Study: 11430781

Group type: EXPERIMENTAL
Intervention: Initial weight for height (WHZ) score
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Initial height for age (HAZ) score
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Lower leg length growth
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Change in HAZ
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Initial WHZ score and maternal height
Number of subjects: 141
Study: 9672452

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9626025

Group type: EXPERIMENTAL
Intervention: Formoterol 24 micrograms twice daily
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms once daily
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Formoterol 6 micrograms twice daily
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Terbutaline 500 micrograms four times daily
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All formoterol regimens
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 1756022

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tissue plasminogen activator
Number of subjects: 0
Study: 7051826

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31792263

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the mPFC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study: 29490640

Group type: EXPERIMENTAL
Intervention: 2, 5 or 8 FV portions/day for 4 weeks
Number of subjects: 30
Study: 26718065

Group type: EXPERIMENTAL
Intervention: Peripheral intravenous cannulae (PIVC) inserted
Number of subjects: 357
Study: 24275895

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression
Number of subjects: 0
Study: 21075578

Group type: EXPERIMENTAL
Intervention: Morphine and ultra-low-dose naltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine alone (with placebo)
Number of subjects: 0
Study: 20207004

Group type: EXPERIMENTAL
Intervention: Parenting skills training (2-hour weekly sessions for 2 weeks)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 224
Study: 18398641

Group type: EXPERIMENTAL
Intervention: Laparoscopic adrenalectomy (n = 13)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Open adrenalectomy (n = 9)
Number of subjects: 22
Study: 15816462

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (500 mg/body) in saline 2 hours before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline alone)
Number of subjects: 40
Study: 12166555

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg) and Loratadine (10 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Loratadine (10 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9672052

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 291

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 291
Study: 8092839

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg once daily for 14 days
Number of subjects: 133

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days
Number of subjects: 133

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 133
Study: 3041830

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Intramuscular cefamandole
Number of subjects: 111
Study: 29633268

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (sCTG)
Number of subjects: 40
Study: 27999758

Group type: EXPERIMENTAL
Intervention: GPC3 peptide vaccine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Best supportive care (control)
Number of subjects: 32
Study: 24986956

Group type: EXPERIMENTAL
Intervention: Ketamine 0.125 mM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine 0.250 mM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no ketamine)
Number of subjects: 0
Study: 22323727

Group type: EXPERIMENTAL
Intervention: Increased activation to houses in the fusiform face area (FFA) with age
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Decreased activation to faces in the extended face network with age
Number of subjects: 300
Study: 20819400

Group type: EXPERIMENTAL
Intervention: Cementation of bands using Resin cement
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cementation of bands using Resin‐modified Glass Ionomer Cement (RMGIC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cementation of bands using conventional Glass Ionomer Cement (GIC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Adaptation of bands without cementation (Control group)
Number of subjects: 48
Study: 19267100

Group type: EXPERIMENTAL
Intervention: Di Bella multitherapy
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Control (not receiving Di Bella multitherapy)
Number of subjects: 1100
Study: 15667759

Group type: EXPERIMENTAL
Intervention: Training in shared decision‐making skills and the use of risk communication materials
Number of subjects: 20
Study: 12846601

Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO) based on a modified Zurich approach in the first year of life
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-infant orthopedics (non-IO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO)
Number of subjects: 12
Study: 10658277

Group type: EXPERIMENTAL
Intervention: Continuous epidural anesthesia
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-epidural anesthesia
Number of subjects: 22
Study: 8673817

Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulphadoxine (PS)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 300
Study: 1442957

Group type: EXPERIMENTAL
Intervention: RU 486 (1 mg/day orally)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 4021969

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment
Number of subjects: 0
Study: 31959002

Group type: EXPERIMENTAL
Intervention: Menu-based health promotion implementation strategies selected by church leaders, including forming a health ministry, allocating space or budget for health activities, and including health in church communications/sermons.
Number of subjects: 3
Study: 30384289

Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 26971533

Group type: EXPERIMENTAL
Intervention: Bosutinib (first-line)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Imatinib (control)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Bosutinib (second-line or later)
Number of subjects: 570
Study: 25100270

Group type: EXPERIMENTAL
Intervention: Concrete rumination
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Abstract rumination
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Abstract conditions
Number of subjects: 136

Group type: COMPARATOR
Intervention: Concrete conditions
Number of subjects: 136
Study: 22570949

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg every 12 hours for 3 months)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 26
Study: 19952722

Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia (33.3 degrees +/- 0.8 degrees C), n = 208
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Supplemental protective drug (thiopental or etomidate), n = 178
Number of subjects: 441

Group type: COMPARATOR
Intervention: Normothermia (36.7 degrees +/- 0.5 degrees C), n = 233
Number of subjects: 441
Study: 17609936

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drug (diclofenac 50 mg)
Number of subjects: 61
Study: 16197471

Group type: EXPERIMENTAL
Intervention: Oral suplatast 300 mg daily for 3 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 12377628

Group type: EXPERIMENTAL
Intervention: Domestically manufactured low-molecular-weight heparin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Imported low-molecular-weight heparin
Number of subjects: 60
Study: 10541777

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ebastine (20 mg)
Number of subjects: 24
Study: 7752640

Group type: EXPERIMENTAL
Intervention: Alcohol (0.35 g/kg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 2271194

Group type: EXPERIMENTAL
Intervention: Droperidol 20 micrograms/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Droperidol 10 micrograms/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Droperidol (both doses)
Number of subjects: 60
Study: 6446106

Group type: EXPERIMENTAL
Intervention: 99mTc-hydroxymethane diphosphonate (HMDP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: 99mTc-methylene diphosphonate (MDP)
Number of subjects: 102
Study: 30985632

Group type: EXPERIMENTAL
Intervention: Single 900-mg oral dose of delafloxacin
Number of subjects: 460

Group type: COMPARATOR
Intervention: Single 250-mg intramuscular ceftriaxone
Number of subjects: 460
Study: 27929185

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol (OHTyr)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red wines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 25355780

Group type: EXPERIMENTAL
Intervention: BiV pacing at 70 b.p.m.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BiV pacing at 90 b.p.m.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BiV pacing at 50 b.p.m.
Number of subjects: 14
Study: 24152211

Group type: EXPERIMENTAL
Intervention: Metronome-paced tachypnoea (MPT) at 40 breaths/min and I:E ratio of 1:1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Incremental exercise testing (XT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bronchodilator treatment
Number of subjects: 24
Study: 20672762

Group type: EXPERIMENTAL
Intervention: Akreos AO IOL (aspheric surface)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Akreos Fit IOL (spherical surface)
Number of subjects: 50
Study: 19048277

Group type: EXPERIMENTAL
Intervention: Proprietary blend of modified cellulose and cetylated fatty acids (Trisynex)
Number of subjects: 22
Study: 16399173

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg for 5 days
Number of subjects: 301

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg for 10 days
Number of subjects: 301
Study: 15592190

Group type: EXPERIMENTAL
Intervention: Tc-99m sestamibi ECG-gated SPECT
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tc-99m sestamibi ECG-gated SPECT with functional data from ECG-gated acquisitions
Number of subjects: 29

Group type: COMPARATOR
Intervention: Successful PTCA in the acute phase of MI
Number of subjects: 29
Study: 11381064

Group type: EXPERIMENTAL
Intervention: 4% lignocaine drop 3 minutes before tropicamide 1%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (nonlignocaine) before tropicamide 1%
Number of subjects: 30
Study: 9006374

Group type: EXPERIMENTAL
Intervention: Fluorouracil/epinephrine gel
Number of subjects: 401

Group type: COMPARATOR
Intervention: Fluorouracil gel alone
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 8433075

Group type: EXPERIMENTAL
Intervention: Dietary fructose (20% of carbohydrate calories, 45‐65 g day‐1 for 4 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control diet (placebo)
Number of subjects: 10
Study: 2825941

Group type: EXPERIMENTAL
Intervention: Isoproterenol, terbutaline, and epinephrine (beta-agonists)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonselective blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta 1‐selective blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta 1‐ and beta 2‐receptor stimulation
Number of subjects: 0
Study: 29545046

Group type: EXPERIMENTAL
Intervention: Modified mechanical percussion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 120
Study: 27281302

Group type: EXPERIMENTAL
Intervention: DHA (2.7 g/d)
Number of subjects: 154
Study: 25182571

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 22429693

Group type: EXPERIMENTAL
Intervention: Health Workshops (8 weekly sessions)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (no participation in Health Workshops)
Number of subjects: 216
Study: 20888307

Group type: EXPERIMENTAL
Intervention: Mannitol 40mg b.i.d.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mannitol 120mg b.i.d.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mannitol 240mg b.i.d.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mannitol 400mg b.i.d.
Number of subjects: 48
Study: 18164939

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 16371580

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA) with selective stent placement
Number of subjects: 279

Group type: COMPARATOR
Intervention: Primary stent placement
Number of subjects: 279
Study: 14650643

Group type: EXPERIMENTAL
Intervention: Asthmatic subjects (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy individuals (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (asthmatic and healthy)
Number of subjects: 20
Study: 11191781

Group type: EXPERIMENTAL
Intervention: Study 1 - Drivers' opinions on adequate, critical, and legal gaps at 40 and 80 km/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study 2 - Judgements of distance to a leading and a following car at 80 km/h
Number of subjects: 0
Study: 8653019

Group type: EXPERIMENTAL
Intervention: Solipid 20% S&E (lipid emulsions based on soy oil with egg lecithin or soy lecithin) administered at 1 g/kg body weight on day 1 and 2 g/kg/day on days 2-5
Number of subjects: 20
Study: 1455403

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 2-4 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 5-6 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 3 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 6 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 3 mg/kg plus infusion of 0.6 mg kg‐1 h‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) 5 mg/kg plus infusion of 1 mg kg‐1 h‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard unfractionated heparin (UFH)
Number of subjects: 6
Study: 4014794

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 20
Study: 30517695

Group type: EXPERIMENTAL
Intervention: Altitude at 1650 m
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Altitude at 2590 m
Number of subjects: 32
Study: 30212961

Group type: EXPERIMENTAL
Intervention: LED applications (intra oral with 660 nm, 12J and extraoral with 850 nm, 108J)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (simulated irradiation)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: LED applications
Number of subjects: 38
Study: 26886262

Group type: COMPARATOR
Intervention: Soccer Training (SG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Resistance Training (RG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 26
Study: 25430452

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block with 0.2% ropivacaine at 5 ml/h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous femoral nerve block with 0.2% ropivacaine at 5 ml/h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups (adductor and femoral)
Number of subjects: 60
Study: 22540635

Group type: EXPERIMENTAL
Intervention: CC + NAC (100 mg/d clomiphene citrate + 1.2 g/d N-acetylcysteine)
Number of subjects: 180

Group type: COMPARATOR
Intervention: CC + Placebo (100 mg/d clomiphene citrate + placebo)
Number of subjects: 180
Study: 20630595

Group type: EXPERIMENTAL
Intervention: Anti-VEGF agent (ranibizumab)
Number of subjects: 40
Study: 17599560

Group type: EXPERIMENTAL
Intervention: Oral corticosteroid treatment
Number of subjects: 0
Study: 15008925

Group type: EXPERIMENTAL
Intervention: Bioactive glass granules mixed with autologous bone chips (BG-AB group)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Autologous bone chips alone (AB group)
Number of subjects: 17
Study: 11548769

Group type: EXPERIMENTAL
Intervention: Leadership program
Number of subjects: 21
Study: 9579850

Group type: EXPERIMENTAL
Intervention: Raltitrexed ('Tomudex')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard 5‐fluorouracil (5‐FU) plus leucovorin (LV)
Number of subjects: 0
Study: 8297690

Group type: EXPERIMENTAL
Intervention: Nifedipine retard (20 mg twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of benazepril and nifedipine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2920133

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 30 mg dihydrocodeine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 4405419

Group type: EXPERIMENTAL
Intervention: Low-dose marijuana (4.8 mg Delta(9)-THC followed by 2.4 mg one hour later)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: High-dose marijuana (9.1 mg Delta(9)-THC followed by 4.5 mg one hour later)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81